ID
45646
Description
Principal Investigator: Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001286 The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was completed in 2006. However, participants have been under follow-up for cancer incidence and mortality since that time. In addition, PLCO included a large biological sample biorepository which has served as a unique resource for cancer research, particularly for etiologic and early-marker studies. As part of these efforts, PLCO has been used for a large number of genome-wide association and exome sequencing studies for different types of cancer.
Link
Keywords
Versions (1)
- 3/20/23 3/20/23 - Simon Heim
Copyright Holder
Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA
Uploaded on
March 20, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001286 The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
Similar models
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
C2348585 (UMLS CUI [1,2])